Evidence map›Paper›PMID 35739306›Full record

ArticleScientific reports2022

Clinical and laboratorial outcome of different age-onset systemic lupus erythematosus patients in Jiangsu, China: a multicentre retrospective study.

Lihui Wen, Ziyan Chen, Ziyi Jin, Wenyou Pan, Lin Liu, Min Wu, Fuwan Ding, Huaixia Hu, Xiang Ding, Hua Wei and 13 more

Abstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Lihui Wen *Department of Rheumatology and Immunology, Affiliated Nanjing Drum Tower Hospital, Medical School of Nanjing University, 321 Zhongshan Road, Nanjing, 210008, China.
Ziyan Chen *Department of Rheumatology and Immunology, Affiliated Nanjing Drum Tower Hospital, Medical School of Nanjing University, 321 Zhongshan Road, Nanjing, 210008, China.
Ziyi JinDepartment of Rheumatology and Immunology, Affiliated Nanjing Drum Tower Hospital, Medical School of Nanjing University, 321 Zhongshan Road, Nanjing, 210008, China.
Wenyou PanDepartment of Rheumatology, Huai'an First People's Hospital, Huai'an, China.
Lin LiuDepartment of Rheumatology, Xuzhou Central Hospital, Xuzhou, China.
Min WuDepartment of Rheumatology, Third Affiliated Hospital of Soochow University, Changzhou, China.
Fuwan DingDepartment of Endocrinology, Yancheng Third People's Hospital, Yancheng, China.
Huaixia HuDepartment of Rheumatology, Lianyungang Second People's Hospital, Lianyungang, China.
Xiang DingDepartment of Rheumatology, Lianyungang First People's Hospital, Lianyungang, China.
Hua WeiDepartment of Rheumatology, Northern Jiangsu People's Hospital, Yangzhou, China.
Yaohong ZouDepartment of Rheumatology, Wuxi People's Hospital, Wuxi, China.
Xian QianDepartment of Rheumatology, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, China.
Meimei WangDepartment of Rheumatology, Southeast University Zhongda Hospital, Nanjing, China.
Jian WuDepartment of Rheumatology, First Affiliated Hospital of Soochow University, Suzhou, China.
Juan TaoDepartment of Rheumatology, Wuxi Hospital of Traditional Chinese Medicine, Wuxi, China.
Jun TanDepartment of Rheumatology, Zhenjiang First People's Hospital, Zhenjiang, China.
Zhanyun DaDepartment of Rheumatology, Affiliated Hospital of Nantong University, Nantong, China.
Miaojia ZhangDepartment of Rheumatology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China.
Jing LiDepartment of Rheumatology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Xuebing FengDepartment of Rheumatology and Immunology, Affiliated Nanjing Drum Tower Hospital, Medical School of Nanjing University, 321 Zhongshan Road, Nanjing, 210008, China.
Jun LiangDepartment of Rheumatology and Immunology, Affiliated Nanjing Drum Tower Hospital, Medical School of Nanjing University, 321 Zhongshan Road, Nanjing, 210008, China. 13505193169@139.com.
Huayong ZhangDepartment of Rheumatology and Immunology, Affiliated Nanjing Drum Tower Hospital, Medical School of Nanjing University, 321 Zhongshan Road, Nanjing, 210008, China. huayong.zhang@nju.edu.cn.
Lingyun SunDepartment of Rheumatology and Immunology, Affiliated Nanjing Drum Tower Hospital, Medical School of Nanjing University, 321 Zhongshan Road, Nanjing, 210008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Studies on clinical features of systemic lupus erythematosus among different age-onset patients are lacking in China. This multicentre study aimed to systemically compare clinical manifestations, comorbidities, organ involvement, and laboratory findings among 797 Chinese juvenile-onset, adult-onset, and late-onset SLE (JSLE, ASLE, and LSLE) patients. They were classified into JSLE, ASLE, and LSLE groups if first diagnosed at < 18, 18-50, and > 50 years old, respectively. Chi-square test and analysis of variance were employed for categorical and continuous variables respectively. In younger-onset patients, the SLE Disease Activity Index 2000 score was significantly higher (JSLE vs. ASLE vs. LSLE = 17.43 ± 9.139 vs. 16.34 ± 8.163 vs. 14.08 ± 6.474, p = 0.031). Mucocutaneous symptoms (79.5% vs. 73.4% vs. 62.0%, p = 0.042), especially malar rash (76.1% vs. 66.1% vs. 53.5%, p = 0.011) occurred more frequently, and proteinuria rate was higher (54.5% vs. 56.3% vs. 36.6%, p = 0.007). In later-onset patients, cardiopulmonary involvement increased (11.4% vs. 24.3% vs. 29.6%, p = 0.012). In ASLE, hypoalbuminemia rate elevated (46.6% vs. 59.9% vs. 47.9%, p = 0.015). Our study demonstrated in a Chinese population that JSLE may be more active and suffer mucocutaneous disorders, while LSLE tended to suffer cardiopulmonary involvement at-onset. These findings may help identify treatment priorities when facing different age-onset SLE patients.

Indexed as

Lupus Erythematosus, SystemicAdultAge of OnsetChi-Square DistributionComorbidityHumansMiddle AgedRetrospective Studies

Identifiers

PMID35739306
PMCPMC9226048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.